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well as reduces the debilitating burden of walking disability in MS patients. Future
studies are required to investigate the direct cost offsets as a result of treatment
with PR-fampridine.
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OBJECTIVES: To estimate the costs of management of children with structural-
metabolic epilepsy and to determine the cost-driving factors in the selected
population. METHODS: This was a retrospective annual prevalence-based study
that included patients who attended a paediatric neurology clinic in a tertiary
referral centre inMalaysia. The total costs of epilepsymanagementwere estimated
from the provider (i.e., hospital) perspective, using a bottom-up,microcosting anal-
ysis. Medical chart/billing data (i.e., case reports) obtained from the hospital (i.e.,
provider) were collected to determine the resources used. Prices or cost data were
standardised for the year 2010. RESULTS: Themost expensive item in the costs list
was antiepileptic drugs, whereas ultrasound examination represented the cheap-
est item. Hospitalisation and the use of non-antiepileptic drugs were the second
and third most costly items, respectively. The cost of therapeutic drug monitoring
comprised only a small proportion of the total annual expenditure. None of the
demographic variables (i.e., gender, race, and age) significantly impacted the an-
nual cost of epilepsy management. Similarly, child development and seizure type
were also not associatedwith the cost ofmanagement. On the other hand, children
who received polytherapy treatment, therapeutic drug monitoring, or adjuvant
therapy with new antiepileptic drugs represented high-cost groups of patients.
Moreover, the total annual cost of epilepsymanagement positively correlated with
seizure frequency. CONCLUSIONS: This investigation was the first cost analysis
study of epilepsy inMalaysia. The total annual cost ofmanagement for 120 patients
with structural-metabolic epilepsy was RM 202,816 (i.e., RM 1690.13 per patient per
year). The study findings highlight the importance of optimizing seizure control in
reducing the cost of management.
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OBJECTIVES:With the ageing of the population, dementia has emerged as a major
public health and economic burden in industrialized countries. Our study aimed at
evaluating direct health care costs in a population of community-dwelling elderly
patients with treated dementia and at comparing such costs with those among
non-demented elderly.METHODS: A retrospective cohort study was conducted in
the community-dwelling elderly population of Quebec using the RAMQ adminis-
trative claims databases (medical services and prescribed medications) and the
Med-Echo hospital discharge database. Patients aged 66 and over, who received at
least one dispensing for a cholinesterase inhibitor (ChI) (donepezil, rivastigmine, or
galantamine) between January 1, 2000 and December 31, 2009 were included in the
cohort of patients with dementia (n37,138). The date of entry in the cohort (index
date) was the date of first dispensing for a ChI during the study period. The com-
parison cohort included elderly patients with no diagnosis of dementia matched
with a 1:1 ratio on age group, gender, and index date. Economic variables included
direct costs of prescribed medications, medical services, hospitalizations and
institutionalization. RESULTS: Overall, our study showed that, at 1 year follow-up,
total health care costs are higher among patients with dementia than among non-
demented elderly (CAD$8360 compared to CAD$5368). Costs associated with ChI
treatment ($1285) andhospitalization ($1103) accounted for the greatest proportion
of the cost difference between the two populations. Over a five-year period, total
health care costswere $38,200 ( $62,180) in the cohortwith dementia compared to
$19,042 ( $31,346) in non-demented elderly. At this time, costs associateed with
institutionalization also contributed significantly to the difference.
CONCLUSIONS: Dementia is an important socioeconomic burden. Despite the
availability of treatments for dementia and the high death rate over a 5-year period,
costs associated with hospitalization and institutionalization increase exponen-
tially, resulting in a major public health burden.
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OBJECTIVES: Patients with neurological conditions such as multiple sclerosis or
spinal cord injurymay experience urinary incontinence resulting from neurogenic
detrusor overactivity (NDO). In addition to reduced quality of life, uncontrolled
NDO can have pathophysiological consequences including urological disorders
and renal failure. Studies have shown that a substantial proportion ofNDOpatients
are inadequately managed by conservative treatments, which include lifestyle
modifications and oral anticholinergicmedication. Recent clinical trials have dem-
onstrated that botulinum toxin type A injections significantly reduce incontinence
frequency. The objective of this study is to examine the cost reductions following
treatment with botulinum toxin type A in NDO patients, in the context of the
Australian health care system. METHODS: Based on data from two Phase III dou-
ble-blinded randomised placebo-controlled trials in NDO patients, a semi-Markov
model was developed to compare treatment with 200U of botulinum toxin type A
versus best supportive care (BSC: pads, catheters, and the option of anticholin-
ergics). Systematic literature searches and a survey of continence nurse practitio-
ners were conducted to source additional information (eg, natural history or re-
source utilisation of NDO patients). The costs considered in themodel include drug
costs, incontinence-related costs (eg, pads, catheterisation), and downstream
health care costs (eg, bladder augmentation surgery). RESULTS: Over a time hori-
zon of 5-years, compared to BSC, botulinum toxin type A treatment results in a
reduction in cost of incontinence pads ($2,445), catheterisation ($592), and a
modest reduction in general practitioner visits ($141) and the likelihood of un-
dergoing bladder augmentation surgery ($235). CONCLUSIONS: Botulinum toxin
typeA treatment is associatedwith cost reductions inNDOpatients and represents
a viable treatment option for NDO patients who are inadequately managed by oral
anticholinergics, and who may otherwise have to consider invasive surgical inter-
ventions.
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The costs of multiple sclerosis (MS) in China are not well known because of com-
paratively low prevalence rate and treatment complexity. OBJECTIVES: To assess
the treatments and costs of MS in China from social perspective by surveying both
patients and physicians.METHODS:Multi-center, questionnaire-based surveywas
conducted in major cities of China to collect health resource utilization, direct and
indirect costs related to MS. An Excel-based model was developed to estimate the
annual cost of MS in China by combining prevalence rate from systematic litera-
ture review, data from surveys and other published information. The costs ofMS in
China were estimated from patient and physician surveys separately and com-
pared with each other. RESULTS: A total of 110 relapsing-remitting multiple scle-
rosis (RRMS) patients and 5 physicians participated the survey. Patients (12.7% age
30; 55.4% age 30-50; and 31.9% age 50 years old) were assessed by Expanded
Disability Status Scale (EDSS) (36% mild; 51% moderate, and 13% sever). The total
cost from patient survey was USD 18,566 (1 USD 6.56 RMB, 2010-2011) (USD 13,265
direct cost and USD 5301 indirect cost) per person year. Total direct cost from
physician survey was USD 10,307 per year (USD 7,137 for medications). Annually
total cost of MS in China, using prevalence data from an epidemiology study, was
estimated to be USD 331.7 million (USD 245.2 million direct costs and USD 86.5
million indirect costs). CONCLUSIONS: The study shows that MS imposes a consid-
erable burden on Chinese patients, especially during disease diagnosis and relapse
periods. Unlike western countries, few patients in China take Disease Modified
Treatments (DMTs) because of the high out of pocket costs. The indirect costs ofMS
are significant and may increase in the near future, which will exacerbate the
burden on individual patients.
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OBJECTIVES: To evaluate the cost-effectiveness analysis of two Disease-modifying
drugs (DMD) used as first-line treatment of Relapsing Remitting Multiple Sclerosis
(RRMS): interferon IFN-1a IM injection (Avonex®) and IFN -1b SC injection (Be-
taferon®) from IranianMinistry of Health perspective.METHODS:A cost-effective-
ness analysis (CEA) was performed fromMinistry of Health (MoH). The outcome of
interest was number of relapses avoided. Costs were reported in 2011 USD. Costs
and outcomes were discounted at 5%. The time horizon was two years. All uncer-
tainties were tested via one-way sensitivity analyses. RESULTS: Total costs per
patient over the time horizon of a study were estimated at 39923, 47670 and 52045
USD for symptom management, IM IFN-1a and SC IFN-1b, respectively. The
incremental cost per relapse avoided was 25823 and 14965 USD for IM IFN-1a and
SC IFN-1b, respectively, compared with no active treatment (symptom manage-
ment). Results were sensitive to the discount rate, frequency of relapse and cost of
DMDs. CONCLUSIONS: The cost-effectiveness analysis determined that INF-1b
SC (Betaferon® ) was the best strategy of the two immunomodulatory therapies
used to treatment of patients experiencing an relapsing-remitting multiple sclero-
sis (RRMS) and resulted in better outcomes than symptom management alone.
Sensitivity analyses indicated that themodel was sensitive to changes in a number
of key parameters, and thus changes in these key parameters would likely influ-
ence the estimated cost-effectiveness results.
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